Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2207

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2207
---

    strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing
    priorities;

    ●
    collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
    candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;

    ●
    collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product
    candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized
    under terms that are more economically attractive than ours;

    ●
    product
    candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates
    or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;

    ●
    collaborators
    may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a
    product candidate or product;

    ●
    collaborators
    with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient
    resources to the marketing and distribution of such product or products;

    ●
    collaborators
    may not provide us with timely and accurate information regarding development progress and activity under any future license agreement,
    which could adversely impact our ability to report progress to our investors and otherwise plan development of our product candidates;

93

    ●
    disagreements
    with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development,
    might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional
    responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming
    and expensive;

    ●
    collaborators
    may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
    litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;

    ●
    collaborators
    may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;

    ●
    if
    a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or
    commercialization